Background and aims Ischemic heart diseases are the main cause of death worldwide,
therefore secondary prevention and treatment of coronary artery disease (CAD) are highly …

BACKGROUND: There is controversy about whether lipid-lowering pharmacotherapy should
be initiated immediately after an acute coronary event or only after diet and lifestyle changes …

Background Patients with acute coronary syndrome (ACS) are at high risk of recurrent
cardiovascular (CV) event. The European guidelines recommend low-density lipoprotein …

Cardiovascular diseases account for 43% of deaths in Poland. The COVID-1 9 pandemic
increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism …

Background A number of clinical trials have shown that patients with overt atherovascular
disease may benefit from more aggressive dosage of statins. We aimed to determined the …

The objective of this prospective cohort study was to describe real-life use of lipid-lowering
drugs and low-density lipoprotein cholesterol (LDL-C) target-attainment rates 1 year after …

Objective Since dyslipidaemia is one of the most important risk factors for coronary heart
disease (CHD), lowering of LDL-cholesterol (LDL-C) causes significant reduction in …

Objectives. Observational studies and surveys have shown that lipid-lowering treatment is
not optimal neither with regard to number of patients treated nor with number of patients …

Cholesterol lowering with statin therapy has been shown to reduce cardiovascular events in
a variety of patient categories, ranging from patients with established cardiovascular disease …

Aim: Early and intensive low-density lipoprotein (LDL-C)-lowering therapy plays important
roles in secondary prevention of acute coronary syndrome (ACS), but the treatment period …